Publisher's Synopsis
This text aims to clarify how to develop and market new drugs efficiently and economically for global markets. It covers the emphasis on over-the-counter drugs in the long-range plans of many companies, and also discusses techniques of institutional review boards (IRBs) and establishment licence applications (ELAs) for biologics in the USA and UK.